These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 3393296)
1. Evidence that the substantia nigra is a site of action for L-DOPA. Robertson GS; Robertson HA Neurosci Lett; 1988 Jun; 89(2):204-8. PubMed ID: 3393296 [TBL] [Abstract][Full Text] [Related]
2. Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms. Robertson GS; Robertson HA J Neurosci; 1989 Sep; 9(9):3326-31. PubMed ID: 2795165 [TBL] [Abstract][Full Text] [Related]
3. Interactions of the tricyclic antidepressant drug amitriptyline with L-DOPA in the striatum and substantia nigra of unilaterally 6-OHDA-lesioned rats. Relevance to motor dysfunction in Parkinson's disease. Kamińska K; Lenda T; Konieczny J; Wardas J; Lorenc-Koci E Neurochem Int; 2018 Dec; 121():125-139. PubMed ID: 30290201 [TBL] [Abstract][Full Text] [Related]
4. Biotransformation of L-dopa in striatum and substantia nigra of rats with a unilateral, nigrostriatal lesion: a microdialysis study. Sarre S; Herregodts P; Deleu D; Devrieze A; De Klippel N; Ebinger G; Michotte Y Naunyn Schmiedebergs Arch Pharmacol; 1992 Sep; 346(3):277-85. PubMed ID: 1407014 [TBL] [Abstract][Full Text] [Related]
5. Simultaneous microdialysis in striatum and substantia nigra suggests that the nigra is a major site of action of L-dihydroxyphenylalanine in the "hemiparkinsonian" rat. Orosz D; Bennett JP Exp Neurol; 1992 Mar; 115(3):388-93. PubMed ID: 1537396 [TBL] [Abstract][Full Text] [Related]
6. Suppression of L-dopa-induced circling in rats with nigral lesions by blockade of central dopa-decarboxylase: implications for mechanism of action of L-dopa in parkinsonism. Melamed E; Hefti F; Bitton V; Globus M Neurology; 1984 Dec; 34(12):1566-70. PubMed ID: 6504328 [TBL] [Abstract][Full Text] [Related]
7. The Effect of Chronic Treatment with the Inhibitor of Phosphodiesterase 5 (PDE5), Sildenafil, in Combination with L-DOPA on Asymmetric Behavior and Monoamine Catabolism in the Striatum and Substantia Nigra of Unilaterally 6-OHDA-Lesioned Rats. Lorenc-Koci E; Kamińska K; Lenda T; Konieczny J Molecules; 2024 Sep; 29(18):. PubMed ID: 39339313 [TBL] [Abstract][Full Text] [Related]
9. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease. Hossain MA; Weiner N J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772 [TBL] [Abstract][Full Text] [Related]
10. L-DOPA modulation of corpus striatal dopamine and dihydroxyphenylacetic acid output from intact and 6-OHDA lesioned rats. Xu K; Dluzen DE J Neural Transm (Vienna); 1996; 103(11):1295-305. PubMed ID: 9013416 [TBL] [Abstract][Full Text] [Related]
11. Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra. Konieczny J; Czarnecka A; Lenda T; Kamińska K; Lorenc-Koci E Behav Brain Res; 2014 Mar; 261():79-88. PubMed ID: 24361083 [TBL] [Abstract][Full Text] [Related]
12. Muscarinic antagonists in substantia nigra influence the decarboxylation of L-dopa in striatum. Izurieta-Sánchez P; Sarre S; Ebinger G; Michotte Y Eur J Pharmacol; 2000 Jul; 399(2-3):151-60. PubMed ID: 10884514 [TBL] [Abstract][Full Text] [Related]
13. The site of dopamine formation in rat striatum after L-dopa administration. Hefti F; Melamed E; Wurtman RJ J Pharmacol Exp Ther; 1981 Apr; 217(1):189-97. PubMed ID: 7205652 [TBL] [Abstract][Full Text] [Related]
14. Altered pharmacokinetics of L-dopa metabolism in rat striatum deprived of dopaminergic innervation. Spencer SE; Wooten GF Neurology; 1984 Aug; 34(8):1105-8. PubMed ID: 6540390 [TBL] [Abstract][Full Text] [Related]
15. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234 [TBL] [Abstract][Full Text] [Related]
16. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions. Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898 [TBL] [Abstract][Full Text] [Related]
17. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978 [TBL] [Abstract][Full Text] [Related]
18. D1 dopamine receptor-mediated substance P depletion in the striatonigral neurons of rats subjected to neonatal dopaminergic denervation: implications for self-injurious behavior. Sivam SP Brain Res; 1989 Oct; 500(1-2):119-30. PubMed ID: 2481560 [TBL] [Abstract][Full Text] [Related]
19. Levodopa induction of Fos immunoreactivity in rat brain following partial and complete lesions of the substantia nigra. Cole DG; Growdon JH; DiFiglia M Exp Neurol; 1993 Apr; 120(2):223-32. PubMed ID: 8491280 [TBL] [Abstract][Full Text] [Related]
20. Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia. Taylor MD; De Ceballos ML; Rose S; Jenner P; Marsden CD Eur J Pharmacol; 1992 Aug; 219(2):183-92. PubMed ID: 1385171 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]